| Artigo em revista |
- Azharuddin M; Roberg K; Dhara AK; Jain MV; Darcy P; Hinkula J; Slater NKH; Patra HK. "Dissecting multi drug resistance in
head and neck cancer cells using multicellular tumor spheroids.". Scientific reports (2019): http://europepmc.org/abstract/med/31882620.
10.1038/s41598-019-56273-6
- Mofers A; Perego P; Selvaraju K; Gatti L; Gullbo J; Linder S; D'Arcy P. "Analysis of determinants for in vitro resistance
to the small molecule deubiquitinase inhibitor b-AP15.". PloS one (2019): http://europepmc.org/abstract/med/31639138.
10.1371/journal.pone.0223807
- Selvaraju K; Mofers A; Pellegrini P; Salomonsson J; Ahlner A; Morad V; Hillert EK; et al. "Cytotoxic unsaturated electrophilic
compounds commonly target the ubiquitin proteasome system.". Scientific reports (2019): http://europepmc.org/abstract/med/31285509.
10.1038/s41598-019-46168-x
- Zhang X; Espinosa B; Saei AA; D'Arcy P; Zubarev RA; Linder S. "Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15
Is Associated with Mitochondrial Impairment.". Oxidative medicine and cellular longevity (2019): http://europepmc.org/abstract/med/31281566.
10.1155/2019/1659468
- Zhang X; Selvaraju K; Saei AA; D'Arcy P; Zubarev RA; Arnér ES; Linder S. "Repurposing of auranofin: Thioredoxin reductase
remains a primary target of the drug.". Biochimie (2019): http://europepmc.org/abstract/med/30946948.
10.1016/j.biochi.2019.03.015
- Hillert EK; Brnjic S; Zhang X; Mazurkiewicz M; Saei AA; Mofers A; Selvaraju K; et al. "Proteasome inhibitor b-AP15 induces
enhanced proteotoxicity by inhibiting cytoprotective aggresome formation.". Cancer letters (2019): http://europepmc.org/abstract/med/30768956.
10.1016/j.canlet.2019.02.003
- Pellegrini P; Serviss JT; Lundbäck T; Bancaro N; Mazurkiewicz M; Kolosenko I; Yu D; et al. "A drug screening assay on cancer
cells chronically adapted to acidosis.". Cancer cell international (2018): http://europepmc.org/abstract/med/30263014.
10.1186/s12935-018-0645-5
- Zhang X; Pellegrini P; Saei AA; Hillert EK; Mazurkiewicz M; Olofsson MH; Zubarev RA; D'Arcy P; Linder S. "The deubiquitinase
inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage.". Biochemical pharmacology (2018): http://europepmc.org/abstract/med/30149015.
10.1016/j.bcp.2018.08.039
- Mazurkiewicz, M.; Hillert, E.-K.; Wang, X.; Pellegrini, P.; Olofsson, M.H.; Selvaraju, K.; D'Arcy, P.; Linder, S.. "Acute
lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition".
Oncotarget 8 13 (2017): 21115-21127. http://www.scopus.com/inward/record.url?eid=2-s2.0-85016431460&partnerID=MN8TOARS.
10.18632/oncotarget.15501
- Arjan Mofers; Paola Pellegrini; Stig Linder; Pádraig D’Arcy. "Proteasome-associated deubiquitinases and cancer". (2017): http://dx.doi.org/10.1007/s10555-017-9697-6.
10.1007/s10555-017-9697-6
- Zhang, X.; Mofers, A.; Hydbring, P.; Olofsson, M.H.; Guo, J.; Linder, S.; D'Arcy, P.. "MYC is downregulated by a mitochondrial
checkpoint mechanism". Oncotarget 8 52 (2017): 90225-90237. http://www.scopus.com/inward/record.url?eid=2-s2.0-85032262517&partnerID=MN8TOARS.
10.18632/oncotarget.21653
- Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; et al. "Corrigendum: The proteasome deubiquitinase
inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.".
Scientific reports (2016): http://europepmc.org/abstract/med/27472448.
10.1038/srep30667
- Wang, X.; Mazurkiewicz, M.; Hillert, E.-K.; Olofsson, M.H.; Pierrou, S.; Hillertz, P.; Gullbo, J.; et al. "The proteasome
deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma
cells". Scientific Reports 6 (2016): http://www.scopus.com/inward/record.url?eid=2-s2.0-84974705319&partnerID=MN8TOARS.
10.1038/srep26979
- Shukla, N.; Somwar, R.; Smith, R.S.; Ambati, S.; Munoz, S.; Merchant, M.; D'Arcy, P.; et al. "Proteasome addiction defined
in Ewing sarcoma is effectively targeted by a novel class of 19S proteasome inhibitors". Cancer Research 76 15 (2016):
4525-4534. http://www.scopus.com/inward/record.url?eid=2-s2.0-84982677746&partnerID=MN8TOARS.
10.1158/0008-5472.CAN-16-1040
- Zhang, X.; De Milito, A.; Demiroglu-Zergeroglu, A.; Gullbo, J.; D'Arcy, P.; Linder, S.. "Eradicating Quiescent Tumor Cells
by Targeting Mitochondrial Bioenergetics". Trends in Cancer 2 11 (2016): 657-663. http://www.scopus.com/inward/record.url?eid=2-s2.0-85000926681&partnerID=MN8TOARS.
10.1016/j.trecan.2016.10.009
- Fryknäs, M.; Zhang, X.; Bremberg, U.; Senkowski, W.; Olofsson, M.H.; Brandt, P.; Persson, I.; et al. "Iron chelators target
both proliferating and quiescent cancer cells". Scientific Reports 6 (2016): http://www.scopus.com/inward/record.url?eid=2-s2.0-85002599978&partnerID=MN8TOARS.
10.1038/srep38343
- D'Arcy, P.; Wang, X.; Linder, S.. "Deubiquitinase inhibition as a cancer therapeutic strategy". Pharmacology and Therapeutics
147 (2015): 32-54. http://www.scopus.com/inward/record.url?eid=2-s2.0-84922605325&partnerID=MN8TOARS.
10.1016/j.pharmthera.2014.11.002
- Wang, X.; D'Arcy, P.; Caulfield, T.R.; Paulus, A.; Chitta, K.; Mohanty, C.; Gullbo, J.; Chanan-Khan, A.; Linder, S.. "Synthesis
and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15". Chemical Biology and Drug Design
86 5 (2015): 1036-1048. http://www.scopus.com/inward/record.url?eid=2-s2.0-84944164063&partnerID=MN8TOARS.
10.1111/cbdd.12571
- Selvaraju, K.; Mazurkiewicz, M.; Wang, X.; Gullbo, J.; Linder, S.; D'Arcy, P.. "Inhibition of proteasome deubiquitinase activity:
A strategy to overcome resistance to conventional proteasome inhibitors?". Drug Resistance Updates 21-22 (2015): 20-29.
http://www.scopus.com/inward/record.url?eid=2-s2.0-84941171799&partnerID=MN8TOARS.
10.1016/j.drup.2015.06.001
- Xiaonan Zhang; Angelo de Milito; Maria Hägg Olofsson; Joachim Gullbo; Padraig D’Arcy; Stig Linder. "Targeting Mitochondrial
Function to Treat Quiescent Tumor Cells in Solid Tumors". (2015): https://doi.org/10.3390/ijms161126020.
10.3390/ijms161126020
- Ma L; Maruwge W; Strambi A; D'Arcy P; Pellegrini P; Kis L; de Milito A; Lain S; Brodin B. "SIRT1 and SIRT2 inhibition impairs
pediatric soft tissue sarcoma growth.". Cell death & disease (2014): http://europepmc.org/abstract/med/25341037.
10.1038/cddis.2014.385
- Dhifaf Sarhan; Padraig D'Arcy; Andreas Lundqvist. "Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System".
(2014): https://doi.org/10.3390/ijms151018557.
10.3390/ijms151018557
- Wang, X.; Stafford, W.; Mazurkiewicz, M.; Fryknäs, M.; Brjnic, S.; Zhang, X.; Gullbo, J.; et al. "The 19S deubiquitinase inhibitor
b-AP15 is enriched in cells and elicits rapid commitment to cell death". Molecular Pharmacology 85 6 (2014): 932-945.
http://www.scopus.com/inward/record.url?eid=2-s2.0-84902986661&partnerID=MN8TOARS.
10.1124/mol.113.091322
- Haglund, C.; Mohanty, C.; Fryknäs, M.; D'Arcy, P.; Larsson, R.; Linder, S.; Rickardson, L.. "Identification of an inhibitor
of the ubiquitin-proteasome system that induces accumulation of polyubiquitinated proteins in the absence of blocking of proteasome
function". MedChemComm 5 3 (2014): 376-385. http://www.scopus.com/inward/record.url?eid=2-s2.0-84895128817&partnerID=MN8TOARS.
10.1039/c3md00386h
- Tian, Z.; D'Arcy, P.; Wang, X.; Ray, A.; Tai, Y.-T.; Hu, Y.; Carrasco, R.D.; et al. "A novel small molecule inhibitor of deubiquitylating
enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance". Blood 123 5 (2014):
706-716. http://www.scopus.com/inward/record.url?eid=2-s2.0-84897022669&partnerID=MN8TOARS.
10.1182/blood-2013-05-500033
- Zhang, X.; Fryknäs, M.; Hernlund, E.; Fayad, W.; De Milito, A.; Olofsson, M.H.; Gogvadze, V.; et al. "Induction of mitochondrial
dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments". Nature Communications
5 (2014): http://www.scopus.com/inward/record.url?eid=2-s2.0-84894542141&partnerID=MN8TOARS.
10.1038/ncomms4295
- D'Arcy, P.; Maruwge, W.; Wolahan, B.; Ma, L.; Brodin, B.. "Oncogenic functions of the cancer-testis antigen SSX on the proliferation,
survival, and signaling pathways of cancer cells". PLoS ONE 9 4 (2014): http://www.scopus.com/inward/record.url?eid=2-s2.0-84899716966&partnerID=MN8TOARS.
10.1371/journal.pone.0095136
- D'Arcy, P.; Linder, S.. "Molecular pathways: Translational potential of deubiquitinases as drug targets". Clinical Cancer
Research 20 15 (2014): 3908-3914. http://www.scopus.com/inward/record.url?eid=2-s2.0-84905453402&partnerID=MN8TOARS.
10.1158/1078-0432.CCR-14-0568
- Sun, C.; Roboti, P.; Puumalainen, M.-R.; Fryknäs, M.; Wang, X.; D'Arcy, P.; Hult, M.; et al. "Elevation of proteasomal substrate
levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases". PLoS ONE 9 10 (2014): http://www.scopus.com/inward/record.url?eid=2-s2.0-84907700366&partnerID=MN8TOARS.
10.1371/journal.pone.0108839
- Brnjic, S.; Mazurkiewicz, M.; Fryknäs, M.; Sun, C.; Zhang, X.; Larsson, R.; D'Arcy, P.; Linder, S.. "Induction of tumor cell
apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress". Antioxidants and Redox Signaling
21 17 (2014): 2271-2285. http://www.scopus.com/inward/record.url?eid=2-s2.0-84912529600&partnerID=MN8TOARS.
10.1089/ars.2013.5322
- Sarhan, D.; D'Arcy, P.; Wennerberg, E.; Lidén, M.; Hu, J.; Winqvist, O.; Rolny, C.; Lundqvist, A.. "Activated monocytes augment
TRAIL-mediated cytotoxicity by human NK cells through release of IFN-¿". European Journal of Immunology 43 1 (2013):
249-257. http://www.scopus.com/inward/record.url?eid=2-s2.0-84872494752&partnerID=MN8TOARS.
10.1002/eji.201242735
- Jarvius, M.; Fryknäs, M.; D'Arcy, P.; Sun, C.; Rickardson, L.; Gullbo, J.; Haglund, C.; et al. "Piperlongumine induces inhibition
of the ubiquitin-proteasome system in cancer cells". Biochemical and Biophysical Research Communications 431 2 (2013):
117-123. http://www.scopus.com/inward/record.url?eid=2-s2.0-84873450879&partnerID=MN8TOARS.
10.1016/j.bbrc.2013.01.017
- Felth, J.; Lesiak-Mieczkowska, K.; D'Arcy, P.; Haglund, C.; Gullbo, J.; Larsson, R.; Linder, S.; et al. "Gambogic acid is
cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system". Investigational New Drugs 31 3 (2013):
587-598. http://www.scopus.com/inward/record.url?eid=2-s2.0-84879116556&partnerID=MN8TOARS.
10.1007/s10637-012-9902-y
- Sarhan, D.; Wennerberg, E.; D'Arcy, P.; Gurajada, D.; Linder, S.; Lundqvist, A.. "A novel inhibitor of proteasome deubiquitinating
activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells". Cancer Immunology,
Immunotherapy 62 8 (2013): 1359-1368. http://www.scopus.com/inward/record.url?eid=2-s2.0-84880910575&partnerID=MN8TOARS.
10.1007/s00262-013-1439-1
- Wennerberg, E.; Sarhan, D.; Carlsten, M.; Kaminskyy, V.O.; D'Arcy, P.; Zhivotovsky, B.; Childs, R.; Lundqvist, A.. "Doxorubicin
sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling". International
Journal of Cancer 133 7 (2013): 1643-1652. http://www.scopus.com/inward/record.url?eid=2-s2.0-84880291938&partnerID=MN8TOARS.
10.1002/ijc.28163
- D'Arcy, P.; Linder, S.. "Proteasome deubiquitinases as novel targets for cancer therapy". International Journal of Biochemistry
and Cell Biology 44 11 (2012): 1729-1738. http://www.scopus.com/inward/record.url?eid=2-s2.0-84864448811&partnerID=MN8TOARS.
10.1016/j.biocel.2012.07.011
- Hernlund, E.; Olofsson, M.H.; Fayad, W.; Fryknäs, M.; Lesiak-Mieczkowska, K.; Zhang, X.; Brnjic, S.; et al. "The phosphoinositide
3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic
therapy". European Journal of Cancer 48 3 (2012): 396-406. http://www.scopus.com/inward/record.url?eid=2-s2.0-84856235027&partnerID=MN8TOARS.
10.1016/j.ejca.2011.11.013
- Gullbo, J.; Fryknäs, M.; Rickardson, L.; Darcy, P.; Hägg, M.; Wickström, M.; Hassan, S.; et al. "Phenotype-based drug screening
in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment".
Biochemical Pharmacology 82 2 (2011): 139-147. http://www.scopus.com/inward/record.url?eid=2-s2.0-79958132098&partnerID=MN8TOARS.
10.1016/j.bcp.2011.04.003
- Sundin, M.; D'Arcy, P.; Johansson, C.C.; Barrett, A.J.; Lönnies, H.; Sundberg, B.; Nava, S.; et al. "Multipotent mesenchymal
stromal cells express FoxP3: A marker for the immunosuppressive capacity?". Journal of Immunotherapy 34 4 (2011): 336-342.
http://www.scopus.com/inward/record.url?eid=2-s2.0-79955583551&partnerID=MN8TOARS.
10.1097/CJI.0b013e318217007c
- Fayad, W.; Rickardson, L.; Haglund, C.; Olofsson, M.H.; D'Arcy, P.; Larsson, R.; Linder, S.; Fryknäs, M.. "Identification
of Agents that Induce Apoptosis of Multicellular Tumour Spheroids: Enrichment for Mitotic Inhibitors with Hydrophobic Properties".
Chemical Biology and Drug Design 78 4 (2011): 547-557. http://www.scopus.com/inward/record.url?eid=2-s2.0-80052640508&partnerID=MN8TOARS.
10.1111/j.1747-0285.2011.01170.x
- D'Arcy, P.; Brnjic, S.; Olofsson, M.H.; Fryknäs, M.; Lindsten, K.; De Cesare, M.; Perego, P.; et al. "Inhibition of proteasome
deubiquitinating activity as a new cancer therapy". Nature Medicine 17 12 (2011): 1636-1640. http://www.scopus.com/inward/record.url?eid=2-s2.0-84856085129&partnerID=MN8TOARS.
10.1038/nm.2536
- D'Arcy, P.; Ryan, B.A.; Brodin, B.. "Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction".
Cancer Letters 275 2 (2009): 285-292. http://www.scopus.com/inward/record.url?eid=2-s2.0-59349107039&partnerID=MN8TOARS.
10.1016/j.canlet.2008.10.030
- Andersson, S.; D'Arcy, P.; Larsson, O.; Sehat, B.. "Focal adhesion kinase (FAK) activates and stabilizes IGF-1 receptor".
Biochemical and Biophysical Research Communications 387 1 (2009): 36-41. http://www.scopus.com/inward/record.url?eid=2-s2.0-67651147931&partnerID=MN8TOARS.
10.1016/j.bbrc.2009.06.088
- Maruwge W; D'Arcy P; Folin A; Brnjic S; Wejde J; Davis A; Erlandsson F; Bergh J; Brodin B. "Sorafenib inhibits tumor growth
and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling.". OncoTargets and therapy (2008):
http://europepmc.org/abstract/med/21127754.
10.2147/ott.s3833
- Wessen Maruwge; Pádraig D’Arcy; Annika Folin; Slavica Brnjic; Johan Wejde. "Sorafenib inhibits tumor growth and vascularization
of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling". (2008): https://doaj.org/article/0de7178671964138b3f8de917e782d8d.
- D'Arcy, P.; Maruwge, W.; Ryan, B.A.; Brodin, B.. "The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by
enhancing HDM2 stability". Molecular Cancer Research 6 1 (2008): 127-138. http://www.scopus.com/inward/record.url?eid=2-s2.0-40749103341&partnerID=MN8TOARS.
10.1158/1541-7786.MCR-07-0176
- Törnkvist, M.; Natalishvili, N.; Xie, Y.; Girnita, A.; D'Arcy, P.; Brodin, B.; Axelson, M.; Girnita, L.. "Differential roles
of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth". Biochemical and Biophysical
Research Communications 368 3 (2008): 793-800. http://www.scopus.com/inward/record.url?eid=2-s2.0-39749166236&partnerID=MN8TOARS.
10.1016/j.bbrc.2008.01.162
- Cronwright, G.; Le Blanc, K.; Götherström, C.; Darcy, P.; Ehnman, M.; Brodin, B.. "Cancer/testis antigen expression in human
mesenchymal stem cells: Down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression". Cancer
Research 65 6 (2005): 2207-2215. http://www.scopus.com/inward/record.url?eid=2-s2.0-16844362032&partnerID=MN8TOARS.
10.1158/0008-5472.CAN-04-1882
|
